These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35743547)

  • 1. Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men Enrolled in Active Surveillance Protocols?
    Pepe P; Roscigno M; Pepe L; Panella P; Tamburo M; Marletta G; Savoca F; Candiano G; Cosentino S; Ippolito M; Tsirgiotis A; Pennisi M
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 68Ga-PSMA PET/CT evaluation in men enrolled in prostate cancer Active Surveillance.
    Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2023 May; 95(2):11322. PubMed ID: 37212907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.
    Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection Rate of
    Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Biopsy in Men High Risk for Prostate Cancer:
    Pepe P; Pennisi M
    Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Gondoputro W; Doan P; Katelaris A; Scheltema MJ; Geboers B; Agrawal S; Liu Z; Yaxley J; Savdie R; Rasiah K; Frydenberg M; Roberts MJ; Malouf D; Wong D; Shnier R; Delprado W; Emmett L; Stricker PD; Thompson J
    Transl Androl Urol; 2023 Oct; 12(10):1598-1606. PubMed ID: 37969779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
    Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
    Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PRIMARY Score: Using Intraprostatic
    Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
    J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
    Lopci E; Lazzeri M; Colombo P; Casale P; Buffi NM; Saita A; Peschechera R; Hurle R; Marzo K; Leonardi L; Morenghi E; Balzarini L; Disconzi L; Guazzoni G; Chiti A; Lughezzani G
    Urol Int; 2023; 107(5):433-439. PubMed ID: 36724746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmatory transperineal saturation prostate biopsy combined with mpMRI decrease the reclassification rate in men enrolled in Active Surveillance: Our experience in 100 men submitted to eight-years scheduled biopsy.
    Pepe P; Pepe L; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2022 Sep; 94(3):270-273. PubMed ID: 36165468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which Prostate Biopsy in Men Enrolled in Active Surveillance? Experience in 110 Men Submitted to Scheduled Three-Years Transperineal Saturation Biopsy Combined With Fusion Targeted Cores.
    Pepe P; Pepe L; Pennisi M; Fraggetta F
    Clin Genitourin Cancer; 2021 Aug; 19(4):305-308. PubMed ID: 33642223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection rate for significant cancer at confirmatory biopsy in men enrolled in Active Surveillance protocol: 20 cores vs 30 cores vs MRI/TRUS fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Barbera M; Panella P; Pennisi M; Morgia G
    Arch Ital Urol Androl; 2016 Dec; 88(4):300-303. PubMed ID: 28073197
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Donato P; Morton A; Yaxley J; Ranasinghe S; Teloken PE; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Roberts MJ
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1843-1851. PubMed ID: 31912257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
    Pepe P; Garufi A; Priolo G; Pennisi M
    World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 18. Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies.
    Bodar Y; Koene B; Meijer D; van Leeuwen PJ; Nadorp S; Donswijk ML; Hendrikse NH; Oprea-Lager DE; Vis AN
    Urol Oncol; 2022 Feb; 40(2):58.e1-58.e7. PubMed ID: 34404590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Utility of
    Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
    Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric Magnetic Resonance Imaging,
    Kubihal V; Sharma S; Kumar R; Seth A; Kumar R; Kaushal S; Sarangi J; Gupta R; Das CJ
    Indian J Nucl Med; 2021; 36(4):362-370. PubMed ID: 35125753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.